10.1007/s11255-023-03817-5 30 DemirS.TuranI.AliyaziciogluR.YamanS
Casein glycomacropeptide (GMP) isolate (24.2%) (from cow's milk ), dried glucose syrup, sucrose, vegetable oils (medium chain triglycerides (coconut and/or palm oil), high oleic sunflower oil, rapeseed oil, sunflower oil), L-leucine, tri calcium phosphate, L-tyrosine, flavouring, magnesium hydrogen phosphate, oligofructose, L-arginine, inulin, L-histidine, resistant starch, gum arabic, potassium chloride, maltodextrin, cellulose, L-valine, choline bitartrate, L-cystine, L-tryptophan, potassium citrate, emulsifier (citric acid esters of mono- and diglycerides of fatty acids, mono- and diglycerides of fatty acids), oil from micro-algae Schizochytrium sp., anticaking agent (E551), modified maize starch, sodium chloride, taurine, inositol, antioxidant (sodium ascorbate, sunflower lecithin, ascorbyl palmitate), L-ascorbic acid, ferrous sulphate, L-carnitine, zinc sulphate, soy fibre, DL--tocopheryl acetate, nicotinamide, calcium D-pantothenate, manganese sulphate, copper sulphate, thiamin hydrochloride, pyridoxine hydrochloride, riboflavin, retinyl acetate, folic acid, -carotene, potassium iodide, chromium chloride, sodium molybdate, sodium selenite, phytomenadione, D-biotin, cholecalciferol, cyanocobalamin Allergy Advice : For allergens, see ingredients in bold
In June 2025, Eli Lilly reported Phase III ACHIEVE-1 Survodutide (BI 456906): Boehringer Ingelhium Survodutide (BI 456906) is a GCGR/GLP1 dual agonist being developed by Boehringer Ingelhium
Your doctor will be able to make this diagnosis
Patients considering lipotropic injections should be counselled that these products are not substitutes for evidence-based weight management strategies and may represent unnecessary expense without proven benefit
